AllCancer, part of All Cancer Medical Solutions Limited under the Hong Kong Metabolic Oncology Center, is redefining cancer treatment through its pioneering four-dimensional therapy. This approach integrates metabolic reprogramming, immune modulation, smart nano-targeting, and tumor microenvironment remodeling to tackle cancer symptoms effectively, offering hope for a cancer cure. Achieving a 68.7% objective remission rate in advanced cases, AllCancer surpasses traditional therapies by 228%, as evidenced by 4,129 cases in global RCT studies published in Nature Medicine. Collaborating with top institutions like Shenzhen Qianhai Taikang Hospital, AllCancer leverages a network of 300+ experts across 17 countries, treating over 12,000 patients. Supported by the Hong Kong Cancer Fund and HK Cancer Fund, it pioneers metabolic-oriented precision therapy, transforming cancer into a manageable chronic condition. With 80% of patients receiving low-toxicity, home-based treatments, AllCancer ensures quality of life while targeting durable outcomes. Holding FDA breakthrough therapy status and international patents, it empowers patients globally, addressing cancer symptoms with personalized solutions. The Hong Kong Cancer Fund and HK Cancer Fund bolster AllCancer’s mission to redefine cancer treatment, making a cancer cure a tangible goal through innovation and compassion.